Fredag 27 December | 03:40:39 Europe / Stockholm

Kalender

Tid*
2025-10-28 07:00 Kvartalsrapport 2025-Q3
2025-08-14 07:00 Kvartalsrapport 2025-Q2
2025-06-04 N/A Årsstämma
2025-04-30 07:00 Kvartalsrapport 2025-Q1
2025-02-12 18:00 Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-16 - Kvartalsrapport 2024-Q2
2024-06-05 - X-dag ordinarie utdelning NAVA 0.00 NOK
2024-06-04 - Årsstämma
2024-04-30 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-01 - Kvartalsrapport 2023-Q3
2023-08-11 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning NAVA 0.00 NOK
2023-06-01 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-08-12 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning NAVA 0.00 NOK
2022-06-02 - Årsstämma
2022-05-10 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-13 - Kvartalsrapport 2021-Q2
2021-06-04 - X-dag ordinarie utdelning NAVA 0.00 NOK
2021-06-03 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-06 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-04 - X-dag ordinarie utdelning NAVA 0.00 NOK
2020-06-03 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-03-11 - Extra Bolagsstämma 2020
2020-02-13 - Bokslutskommuniké 2019
2019-11-01 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-29 - X-dag ordinarie utdelning NAVA 0.00 NOK
2019-05-28 - Årsstämma
2019-05-15 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018
2018-12-20 - Extra Bolagsstämma 2018
2018-11-09 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-06-08 - X-dag ordinarie utdelning NAVA 0.00 NOK
2018-06-07 - Årsstämma
2018-05-30 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-07-28 - Kvartalsrapport 2017-Q2
2017-06-07 - X-dag ordinarie utdelning NAVA 0.00 NOK
2017-06-06 - Årsstämma
2017-05-10 - Kvartalsrapport 2017-Q1
2017-02-15 - Bokslutskommuniké 2016
2017-01-13 - Extra Bolagsstämma 2017
2016-11-11 - Kvartalsrapport 2016-Q3
2016-08-18 - Kvartalsrapport 2016-Q2
2016-06-21 - X-dag ordinarie utdelning NAVA 0.00 NOK
2016-06-20 - Årsstämma
2016-05-11 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-10-30 - Extra Bolagsstämma 2015
2015-10-30 - Kvartalsrapport 2015-Q3
2015-08-21 - Kvartalsrapport 2015-Q2
2015-06-09 - X-dag ordinarie utdelning NAVA 0.00 NOK
2015-06-08 - Årsstämma
2015-04-28 - Kvartalsrapport 2015-Q1
2015-02-27 - Bokslutskommuniké 2014
2014-10-31 - Kvartalsrapport 2014-Q3
2014-08-22 - Kvartalsrapport 2014-Q2
2014-06-10 - Årsstämma
2014-05-06 - Kvartalsrapport 2014-Q1
2014-02-27 - Bokslutskommuniké 2013
2013-11-01 - Kvartalsrapport 2013-Q3
2013-08-30 - Kvartalsrapport 2013-Q2
2013-06-13 - Kapitalmarknadsdag 2013
2013-05-23 - Årsstämma
2013-04-25 - Kvartalsrapport 2013-Q1
2013-02-15 - Bokslutskommuniké 2012
2012-02-10 - Bokslutskommuniké 2011
2011-10-21 - Kvartalsrapport 2011-Q3
2011-08-25 - Kvartalsrapport 2011-Q2
2011-05-05 - Kvartalsrapport 2011-Q1
2011-04-14 - Årsstämma
2011-02-04 - Bokslutskommuniké 2010
2010-10-28 - Kvartalsrapport 2010-Q3
2010-08-26 - Kvartalsrapport 2010-Q2
2010-05-05 - Kvartalsrapport 2010-Q1
2010-03-25 - Årsstämma
2010-02-11 - Bokslutskommuniké 2009

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Navamedic är ett nordiskt läkemedelsföretag som levererar läkemedel, OTC, medicinska nutritionsprodukter för sällsynta diagnoser samt medicintekniska produkter till sjukhus och apotek inom områden som exempelvis obesitas, kvinnohälsa, urologi, mage/tarm, samt smärta. Navamedic verkar i de nordiska länderna, Baltikum och Benelux men är även representerade i Storbritannien och Grekland. Bolaget etablerades 1999 med säte i Oslo.
2023-05-11 08:00:19
Oslo, 11 May 2023 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and
reliable provider of high-quality products to hospitals and pharmacies, today
announces its results for the first quarter of 2023. Navamedic experienced good
momentum across the business and delivered another strong quarter, with record
high revenues of NOK 121.7 million, representing an increase of 93.3 per cent
compared to the first quarter of 2022.

In the first quarter of 2023, Navamedic's gross margin was 41.3 per cent, an
increase from 39.4 per cent from the corresponding quarter in 2022. EBITDA for
the quarter was NOK 15.8 million compared to NOK -0.4 million in the first
quarter of 2022. Operating profit (EBIT) amounted to NOK 13.9 million compared
to NOK -2.2 million in the same quarter last year. Additionally, Navamedic
achieved organic growth of 70.5 per cent compared to the first quarter of 2022.

"We have had a strong start to 2023, and we are now well on our way to becoming
a NOK 1 billion company. Our growth is driven by the successful build-up of our
diversified product categories, and we have experienced continued demand for
products across our business areas," commented Kathrine Gamborg Andreassen, CEO
of Navamedic.

Increased demand has resulted in revenue growth across the company's three core
business areas: Prescription drugs (RX), Consumer Health and Hospital.

At the end of the period and in line with Navamedic's M&A strategy, the company
announced it had submitted a recommended cash offer to acquire all shares in
Sweden-based Sensidose AB, a pharmaceutical company targeting patients with
advanced Parkinson's disease. Sensidose AB sells drugs in combination with an
innovative medical device for individual dosing. As of 10 May, Navamedic held
6.9 million (57.9 per cent) shares in Sensidose AB and 426,577 warrants of
series TO 1.

Post-period, Navamedic acquired the rights to distribute and sell Alflorex®, an
over-the-counter product for irritable bowel syndrome (IBS), in Sweden. The
agreement follows Navamedic's initial agreement with Novozymes in 2019, and with
additional rights to distribute Alflorex® in Sweden, Navamedic has increased its
market share in Sweden.

Navamedic will host a presentation on Thursday,11 May, starting at 08.30 CEST.
The presentation will take place at Dronning Eufemias Gate 16 in Oslo, and will
be available to follow via webcast at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230511_4

Representatives from Navamedic's management team, CEO Kathrine Gamborg
Andreassen and CFO Lars Hjarrand will host the presentation.

The presentation will also be made available at
www.navamedic.com/investors/financial-results.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
attached first quarter presentation on slide 26.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.